Product Description: Lenvima (Lenvatinib)

Lenvima, also known as Lenvatinib, is a targeted therapy medication used in the treatment of various types of cancer, including thyroid cancer, hepatocellular carcinoma (HCC), and renal cell carcinoma (RCC). It works by inhibiting multiple receptor tyrosine kinases, which play a crucial role in tumor growth and angiogenesis.

Indications

• Treatment of differentiated thyroid cancer
• Hepatocellular carcinoma in combination with everolimus
• Renal cell carcinoma in combination with pembrolizumab

Mechanism of Action

Lenvatinib inhibits the activity of several receptor tyrosine kinases, including VEGFR, FGFR, PDGFR, and RET, which are involved in the proliferation and survival of cancer cells. By blocking these pathways, Lenvima effectively slows down tumor growth and reduces the formation of new blood vessels that supply the tumor.

Dosage and Administration

The dosage of Lenvima is determined based on the specific indication and the patient's overall health. It is typically administered orally once daily, with or without food. Patients should follow their healthcare provider's instructions regarding dosage adjustments and duration of treatment.

Side Effects

Common side effects of Lenvima may include:

• Hypertension
• Fatigue
• Diarrhea
• Nausea
• Weight loss

Patients should report any severe or persistent side effects to their healthcare provider.

Precautions

Before starting Lenvima, patients should inform their healthcare provider of any pre-existing conditions, especially cardiovascular issues, liver disease, or a history of bleeding disorders. Regular monitoring of blood pressure and liver function is recommended during treatment.

Conclusion

Lenvima (Lenvatinib) represents a significant advancement in cancer therapy, offering targeted treatment options for patients with specific types of tumors. As with any medication, it is essential for patients to discuss their treatment plan with their healthcare provider to ensure optimal results.